Iswarya Fertility Center raises over ₹350 Crore from OrbiMed Asia

Chennai-based Iswarya Fertility Center has announced a growth investment of more than ₹350 crore (around US$37 million) from OrbiMed Asia (OrbiMed), a global healthcare investment firm.

The investment marks a significant milestone in Iswarya’s mission to expand the reach of fertility care across India and help address the country’s declining birth rates.

Established in 1986, Iswarya has a fertility network of 85+ centres across eight states, serving more than 300,000 couples over four decades. Today, the company is offering its services spanning IVF, IUI, fertility preservation, genetics, and advanced reproductive treatments.

The investment will enable Iswarya to establish new centers in existing and underserved markets, strengthen clinical infrastructure, invest in digital capabilities and expand its embryology talent pipeline.

Expanding the availability of quality fertility care is emerging as an important healthcare need and a national demographic priority. Iswarya plans to deepen its presence in existing markets, enter underserved geographies and continue investing in clinical excellence, medical education and innovation.

“We will invest in our people, technology and patient experience, ensuring that excellence remains at the heart of everything we do. We are delighted to welcome OrbiMed as our partner on this journey,” Dr. Arun Muthuvel, Managing Director, Iswarya Fertility Center, said.

Dr. Sunny Sharma, Partner and Senior Managing Director, and Arun Sadhanandham, Managing Director at OrbiMed, said in a joint statement, “Iswarya has established itself as one of the country’s leading fertility platforms through its strong clinical outcomes, trusted brand, capital-efficient operating model, and experienced leadership team.”

Veda Corporate Advisors were the financial advisors to the company and its promoters.